Is Selling Stock Like Cipher Pharmaceuticals Inc After Such Decline Winning Strategy?

 Is Selling Stock Like Cipher Pharmaceuticals Inc After Such Decline Winning Strategy?

The stock of Cipher Pharmaceuticals Inc (TSE:CPH) is a huge mover today! About 36,210 shares traded hands or 38.90% up from the average. Cipher Pharmaceuticals Inc (TSE:CPH) has declined 46.72% since April 11, 2016 and is downtrending. It has underperformed by 52.86% the S&P500.
The move comes after 7 months negative chart setup for the $114.41 million company. It was reported on Nov, 11 by Barchart.com. We have $3.48 PT which if reached, will make TSE:CPH worth $14.87 million less.

Cipher Pharmaceuticals Inc (TSE:CPH) Ratings Coverage

Out of 2 analysts covering Cipher Pharmaceuticals (TSE:CPH), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cipher Pharmaceuticals has been the topic of 2 analyst reports since August 12, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating by TD Securities given on Friday, August 12. The firm has “Hold” rating by GMP Securities given on Friday, August 12.

More recent Cipher Pharmaceuticals Inc (TSE:CPH) news were published by: Finance.Yahoo.com which released: “Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call” on October 27, 2016. Also Prnewswire.com published the news titled: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016. Prnewswire.com‘s news article titled: “Cipher Pharmaceuticals Inc. announces Sitavigâ„¢ accepted for review by Health …” with publication date: February 16, 2016 was also an interesting one.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The company has a market cap of $114.41 million. The Firm has a portfolio of commercial and late-stage products. It currently has negative earnings. It operates in the specialty pharmaceuticals segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment